Interactions of C-reactive protein and complement with liposomes.
Interactions between C-reactive protein (CRP) and liposomal model membranes containing phosphatidylcholine were investigated. These interactions, in the presence of human serum, resulted in consumption of each of the components of the classical complement pathway (C1-C9) and also resulted in complement-dependent damage and release of trapped glucose from certain types of liposomes. CRP-initiated lysis of liposomes was strongly dependent upon membrane lipid composition. Optimal activity occurred with positively charged liposomes containing galactosylceramide (galactocerebroside); positively charged liposomes lacking galactocerebroside released much less glucose, while negatively charged liposomes, either with or without galactocerebroside, did not release glucose at all. Glucose release was inhibited by free phosphocholine. Lesser, but significant, "background" glucose release independent of the presence of CRP also was observed with positively charged liposomes containing galactocerebroside, and this was associated with marked preferential consumption of the later-acting complement components (C3-C9). C2-deficient human serum failed to support CRP-dependent glucose release, but glucose release was observed upon reconstitution of the serum with C2. Guinea pig complement also did not support CRP-mediated glucose release, but upon addition of human C1q substantial glucose release was observed. We conclude that (i) CRP can sensitize appropriate liposomes for complement-dependent damage via the primary complement pathway starting at the level of C1q; (ii) of those studied, liposomes that are most susceptible to membrane damage contain phosphatidylcholine, have a positive charge, and contain a ceramide glycolipid; and (iii) such liposomes also are sensitive, although to a much lesser degree, to complement-dependent lysis initiated in the absence of CRP and involving consumption of terminal in excess of early acting complement components.
D002097:C-Reactive Protein / Q000378:metabolism*; D002554:Cerebrosides; D003165:Complement System Proteins / Q000378:metabolism*; D005947:Glucose / Q000378:metabolism; D008081:Liposomes; D008563:Membrane Lipids; D010713:Phosphatidylcholines
D002554:Cerebrosides; D008081:Liposomes; D008563:Membrane Lipids; D010713:Phosphatidylcholines; D003165:Complement System Proteins; D002097:C-Reactive Protein; D005947:Glucose
J Exp Med. 1975 Sep 1;142(3):709-21
809531
J Immunol. 1977 Jan;118(1):342-7
830757
Biochim Biophys Acta. 1975 Sep 16;406(1):97-107
1174576
J Lab Clin Med. 1976 Jan;87(1):120-8
1245780
J Immunol. 1974 Jun;112(6):2135-47
4151108
J Immunol. 1974 Jul;113(1):9-17
4208926
Biochem J. 1968 Dec;110(3):573-82
4387389
Proc Soc Exp Biol Med. 1971 Feb;136(2):612-4
4395924
Methods Enzymol. 1974;32:501-13
4444535
J Exp Med. 1974 Sep 1;140(3):631-47
4472155
Biochim Biophys Acta. 1972 Feb 14;265(1):1-23
4554562
Proc Natl Acad Sci U S A. 1969 Sep;64(1):290-5
5263014
Immunology. 1970 Dec;19(6):983-6
5530596
J Immunol. 1971 Feb;106(2):304-13
5545135
Acta Med Scand Suppl. 1961;361:1-71
13712705
Proc Natl Acad Sci U S A. 1967 Mar;57(3):706-12
16591521